结肠造口结肠癌原位移植模型的建立  

Establishment of colostomy orthotopic transplantation mice and study on their biological characteristics

作　　者：金黑鹰[1] 刘秀芳[1] 丁义江[1] 恽时锋[2] 刘飞[1] 

机构地区：[1]南京中医药大学第三附属医院全国肛肠医疗中心,江苏南京210001 [2]南京军区南京总医院核医学科

出　　处：《中华胃肠外科杂志》2009年第3期294-296,共3页Chinese Journal of Gastrointestinal Surgery

基　　金：国家自然科学基金（30572447）;南京市医学发展重点项目（ZKX05028）.

摘　　要：目的建立一种新型的结肠癌原位移植模型—结肠造口结肠癌原位移植模型。方法对不同的BALB／C nu／nu裸鼠分别进行皮下结肠癌细胞接种和进行结肠造口，将皮下形成的肿瘤制成细胞悬液后种植在造口处，待肿瘤生长至5mm时使用氟尿嘧啶（5-Fu）腹腔注射。观察肿瘤生长、淋巴结转移及肿瘤的病理情况。结果10只造口成功的裸鼠全部生长出肿瘤，5只5-Fu处理组裸鼠的生存时间为（15.2±3.7）周，未处理组生存时间为（12.3±2.8）周，差异有统计学意义（P=0.001）。处理组中1例发现淋巴结转移，而未处理组有2例淋巴结转移（P=0.49）。病理检查：造口处生长的肿瘤皆为低分化癌，肠系膜淋巴结处为转移性肿瘤。结论结肠造口结肠癌原位移植模型是一种便于观察、可以反复取样且肿瘤生物学特性符合结肠癌的理想模型。Objective To establish a colorectal cancer colostomy orthotopic transplantation mice model. Methods A colostomy was preformed in BALB/C nu-nu nude mice. After two weeks, when the stoma healed, tumor tissues developed from Lovo cells were implanted into the submucosa of the stoma. When tumor grew up to 5 mm, fluorouracil（5-FU, 20mg/kg） was administrated by intraperitoneal injection. Tumor developed at the colostomy was observed and its biological characteristics and behaviour were evaluated. Results Colostomy was performed in 10 mice and stoma healed at two weeks. Ten colostomies developed detectable tumor in two to three weeks. Three to five weeks later, the tumors grew up to 5 mm. Survival time of mice injected with 5-FU was （15.2±3.7） weeks （ranged： 11-21 weeks）, and the survival time of the no-treantment group was （12.3±2.8） weeks （ranged：9-19 weeks）. The difference was statistically significant （P=0.001）. The rate of mesenteric metastasis was 1/5 and 2/5 in the treatment and no-treatment group respectively. Conclusion Colostomy orthotopic transplantation mice model is an ideal mice model with the advantages of having high success rate, visualization of implanted tumor in living animal, long survival time and significant tumor response to common chemotherapeutic agent.

关 键 词：结直肠肿瘤 模型 动物 结肠造口 生物学特征 

分 类 号：R735[医药卫生—肿瘤] R-332[医药卫生—临床医学]